(2/2) In patients with ACS and scheduled PCI, prasugrel reduces CV morbidity and mortality but increases bleeding when compared to clopidogrel.
#FOAMcards
(1/2)Trial of the day: TRITON-TIMI 38
Wiviott ST, et al. "Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes". The New England Journal of Medicine. 2007. 357(20):2001-2015.
https://t.co/PnaFaNhjQt
#FOAMcards
(1/2)Trial of the day: ACCORD BP
ACCORD Study Group. "Effects of intensive blood-pressure control in type 2 diabetes mellitus". The New England Journal of Medicine. 2010. 362(17):1575-1585.
https://t.co/r8aODK0TGr
#FOAMcards
(2/2) In patients with T2DM at high risk for CV events, targeting SBP <120 mmHg did not reduce rates of nonfatal MI, nonfatal stroke, or CV mortality when compared to a target SBP <140 mmHg.
#FOAMcards
(2/2) Among patients with symptomatic carotid artery stenosis, carotid endarterectomy (CEA) reduces the risk of major stroke or death in those whose carotid stenosis is ≥80%.
#FOAMcards
(1/2)Trial of the day: ECST
ECST Writers. "Randomised trial of endarterectomy for recently symptomatic carotid stenosis: Final results of the MRC European Carotid Surgery Trial (ECST)". The Lancet. 1998. 351(9113):1379-1387.
https://t.co/b6GvinL9E7
#FOAMcards
(2/2) Female Younger age Exposure to childhood familial violence Physical or mental disability Use of alcohol by either party Lower SES Immigrants
#FOAMcards
(2/2) In patients with prior stroke/TIA, atorvastatin reduces risk of recurrent ischemic stroke, but may increase risk of hemorrhagic stroke.
#FOAMcards
(1/2)Trial of the day: SPARCL
Amarenco P, et al. "High-dose atorvastatin after stroke or transient ischemic attack". The New England Journal of Medicine. 2006. 355(6):549-559.
https://t.co/P0Ssf8WMBL
#FOAMcards
(2/2) Among patient with COPD and mMRC dyspnea grade ≥2 symptoms, indacaterol+glycopyrronium (LABA+LAMA) is associated with a reduction in the rate of annual COPD exacerbations when compared to salmeterol+fluticasone (LABA+ICS).
#FOAMcards